Alessandro della Chà

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada.

The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom.

Touch Bionics Ltd. provides prosthetic technologies and supporting services for the people with upper limb deficiencies. Its products develop upper-limb prosthetic technologies and specializes in myoelectronic hand and partial hand solutions, as well as a realistic silicone prostheses that are designed to closely match the skin of the wearer. Touch Bionics was founded in 2003 by David Gow and is headquartered in Livingston, the United Kingdom.

Innovate UK promotes, supports and invests in technology research, development, and commercialization. The firm provides access to information about the funding and support opportunities through a range of channels. The company was founded on July 1, 2007 and is headquartered in Swindon, the United Kingdom.

Calcivis Ltd. provides dental assessment services. The firm offers preventive dentistry, CALCIVIS photoprotein, and CALCIVIS imaging devices. The company was founded by Adam Christie and Bruce Vernon in 2012 and is headquartered in Edinburgh, the United Kingdom.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

The Royal Society of Edinburgh provides investment advice. The non-profit company is based in Edinburgh, UK and has subsidiaries in the United Kingdom.

Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom.

BBI Diagnostics Group 2 Plc provides diagnostic tests and materials. It offers a portfolio of products and services that are provided to the diagnostic, healthcare, research, defense, and food industries. The company was founded on October 22, 2013 and is headquartered in Bedford, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

BioCity Nottingham Ltd (BioCity) is a venture capital firm founded in 2002. The firm is headquartered in London, United Kingdom.

Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd.

Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015.

AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.

Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA.

Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables.

CXR Biosciences Ltd. provides drug development solutions and investigative toxicology services. Its drug development solutions include bioavailability, patient response variation, drug and drug interactions, drug reactions, toxicity, reactive metabolites, customized assay development, and anticancer drug development services. The firm serves pharmaceutical, biotech, agrochemical, consumer product, and fine chemical industries. The company was founded by Clifford Roy Elcombe and Roland Charles Wolf in December 2001 and is headquartered in Dundee, the United Kingdom.

The Roslin Institute conducts genetic research on animal and human health. It focuses on health and welfare of animals, and applications of basic animal sciences in human and veterinary medicine, the livestock industry and food security. The company was founded on April 1, 1993 and is headquartered in Midlothian, the United Kingdom.

Amerigen Pharmaceuticals Ltd. engages in the development, manufacturing, and sale of generic pharmaceutical products. The company was founded in 2007 and is headquartered in Lyndhurst, NJ.